Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06804103 in HER2+ and HER2- Solid Tumors
NCT03284723Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Nov 2017
- Primary completion
- Aug 2021
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 6
01
Overview
Phase 1, open-label trial of PF-06804103 in breast cancer and gastric cancer (GC) (2 arms), sponsored by Pfizer. Primary endpoints: Dose-Limiting Toxicities, Treatment Emergent Adverse Events and 6 more. Started Nov 2017; status: terminated.
02
Drugs
PF-06804103
03
Conditions
breast cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT03284723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03284723.